ClinicalTrials.gg
CompletedNCT00875056Updated Jan 30, 2026Results posted

Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)

A Phase 2 interventional study of Vorinostat in Lymphoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing vorinostat in Lymphoma — none open to participants now, 1 under way, 1 of them phase 3. Vorinostat · Lymphoma.

Enrollment
4th of 19
56 · median 17
Started
2009
with 3 others
Phase 2
5 of 20
none open now
Registered
10th of 20
by date
Lead sponsor
4 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing vorinostat in Lymphoma, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2009, is one of 5 in phase 2, and was the 10th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 435 are open to participants now.

Browse Lymphoma studies →

Open to participants now

None of the 20 studies testing vorinostat in Lymphoma is open now. The open studies under Lymphoma, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 347 Lymphoma studies recruiting now, 228 (66%) set no upper age limit and 78 (22%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing vorinostat in Lymphoma as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of vorinostat (MK-0683) in participants with relapsed and/or refractory follicular lymphoma. The exploratory purpose of this study is to evaluate efficacy of MK-0683 in participants with relapsed/refractory non-FL indolent B-NHL or relapsed/refractory MCL. The primary hypothesis is that MK-0683 will show efficacy in relapsed/refractory FL patients as measured by the Overall Response Rate.

03

Conditions studied

  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has an histopathologically confirmed follicular lymphoma (FL), or other indolent B-cell non-Hodgkin's lymphoma (B-NHL) or mantle cell lymphoma (MCL)

    • Only FL can be included outside Japan
  • Participant has at least one by computerized tomography (CT) scan which is defined by Cheson's 1999 criteria
  • Participant has received at least 1 but up to 4 prior chemotherapeutic regimens, the most recent therapy must have failed to induce a partial response, or there must be recurrence in case of the most recent therapy has shown complete response, or there must be relapse in case of the most recent therapy has shown partial response
  • of >4 months
  • Participant must have adequate organ and marrow function
  • Women of child bearing potential must be negative for pregnancy and agree to use effective measures until 30 days after the last dose of MK-0683.
  • Men must agree to use effective contraceptive measures until 6 months after the last dose of MK-0683

Exclusion criteria

Exclusion Criteria:

  • Participant has undergone allogenic transplant treatment or stem cell transplant within 6 months
  • Participant with other active or central neurological infiltration with lymphoma
  • Participant with severe hepatic insufficiency
  • Participant with history of allergic reactions attributed to any component of MK-0683
  • Participant is known to be (HIV) antibody-, virus antigen- or virus antibody-positive
  • Participant has undergone prior/concomitant treatment with MK-0683 or other histone deacetylase (HDAC) inhibitors
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Follicular Lymphoma (FL)

    Participants with relapsed/refractory FL received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.

    Drug: Vorinostat

  • Experimental
    Indolent non-FL B-NHL or MCL

    Participants with indolent non-follicular lymphoma (FL) B-cell non-Hodgkin's lymphoma (B-NHL), or with mantle cell Lymphoma (MCL) received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.

    Drug: Vorinostat

  • Experimental
    Other Disease

    Participants with disease other than relapsed/refractory follicular lymphoma (FL), non-FL B-cell non-Hodgkin's lymphoma (B-NHL), or mantle cell Lymphoma (MCL), as assessed by the Independent Central Pathological Committee, received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol. This group was created to include participants who enrolled, but whose later diagnoses by the Independent Central Pathological Committee excluded them from analysis in the FL and non-FL B-NHL/MCL groups because they had different disease than those prespecified in the protocol.

    Drug: Vorinostat

Interventions

  • Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle

    Also known as: MK-0683, Zolinza

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who had a Complete Response (CR: Normal liver/spleen physical exam, all lymph nodes and nodal masses are normal, and there is no bone marrow involvement), a Complete Response/unconfirmed (CRu: Normal liver/spleen physical exam, plus at least a 75% decrease in the sum of the products of the greatest diameters of nodal masses if any are greater than 1.5 cm in their greatest diameter, normal or indeterminate bone marrow involvement), or a Partial Response (PR: Either normal physical exam, lymph nodes, and lymph node masses plus positive bone marrow involvement; OR normal physical exam or decrease in liver/spleen size plus at least a 50% decrease in the diameters of lymph nodes and nodal masses) as assessed using the international working group Non-Hodgkin's lymphoma standardized response criteria described by Cheson, BD in 1999. The percentage of participants who experienced a CR, CRu, or PR is presented.

    Time frame: Up to 650 days

  2. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE was presented.

    Time frame: Up to approximately 29 months

  3. Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event (AE)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued from study drug due to an adverse event was reported.

    Time frame: Up to 536 days

Secondary outcomes

  1. Time to Treatment Failure for Relapsed/Refractory FL

    Time to Treatment Failure is defined as the time from allocation until the date of any treatment failure, including documented disease progression, or discontinuation of the study medication for any reason. Data was censored on the efficacy data cutoff date of 25 February, 2011.

    Time frame: Up to 650 days

  2. Time to Response for Relapsed/Refractory FL

    Time to Response is defined as the time from allocation until the time of an initial response. Data was censored on the efficacy data cutoff date of 25 February, 2011.

    Time frame: Up to 650 days

07

Results

Posted Oct 29, 2020

Participant flow

Participant flow — Overall Study
MilestoneFollicular Lymphoma (FL)Indolent Non-FL B-NHL or MCLOther Disease
Started39116
Completed520
Not completed3496
Withdrew: Adverse event812
Withdrew: Physician decision200
Withdrew: Progressive disease2083
Withdrew: Withdrawal by subject401

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who had a Complete Response (CR: Normal liver/spleen physical exam, all lymph nodes and nodal masses are normal, and there is no bone marrow involvement), a Complete Response/unconfirmed (CRu: Normal liver/spleen physical exam, plus at least a 75% decrease in the sum of the products of the greatest diameters of nodal masses if any are greater than 1.5 cm in their greatest diameter, normal or indeterminate bone marrow involvement), or a Partial Response (PR: Either normal physical exam, lymph nodes, and lymph node masses plus positive bone marrow involvement; OR normal physical exam or decrease in liver/spleen size plus at least a 50% decrease in the diameters of lymph nodes and nodal masses) as assessed using the international working group Non-Hodgkin's lymphoma standardized response criteria described by Cheson, BD in 1999. The percentage of participants who experienced a CR, CRu, or PR is presented.

Time frame:
Up to 650 days
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsFollicular Lymphoma (FL)Indolent Non-FL B-NHL or MCLOther Disease
Objective Response Rate (ORR)48.7 (32.4 to 65.2)27.3 (6.0 to 61.0)—
PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE was presented.

Time frame:
Up to approximately 29 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsFollicular Lymphoma (FL)Indolent Non-FL B-NHL or MCLOther Disease
Number of Participants Who Experienced an Adverse Event (AE)39116
SecondaryTime to Treatment Failure for Relapsed/Refractory FL

Time to Treatment Failure is defined as the time from allocation until the date of any treatment failure, including documented disease progression, or discontinuation of the study medication for any reason. Data was censored on the efficacy data cutoff date of 25 February, 2011.

Time frame:
Up to 650 days
Reported as:
Median · Days
Time to Treatment Failure for Relapsed/Refractory FL
DaysFollicular Lymphoma (FL)Indolent Non-FL B-NHL or MCLOther Disease
Time to Treatment Failure for Relapsed/Refractory FL323 (60 to NA)——
SecondaryTime to Response for Relapsed/Refractory FL

Time to Response is defined as the time from allocation until the time of an initial response. Data was censored on the efficacy data cutoff date of 25 February, 2011.

Time frame:
Up to 650 days
Reported as:
Median · Days
Time to Response for Relapsed/Refractory FL
DaysFollicular Lymphoma (FL)Indolent Non-FL B-NHL or MCLOther Disease
Time to Response for Relapsed/Refractory FLNA (NA to NA)——
PrimaryNumber of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event (AE)

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued from study drug due to an adverse event was reported.

Time frame:
Up to 536 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event (AE)
ParticipantsFollicular Lymphoma (FL)Indolent Non-FL B-NHL or MCLOther Disease
Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event (AE)612

Adverse events

Collected over Up to approximately 65 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Follicular Lymphoma (FL)9/39 (23.1%)15/39 (38.5%)39/39 (100%)
Indolent Non-FL B-NHL or MCL4/11 (36.4%)4/11 (36.4%)11/11 (100%)
Other Disease3/6 (50%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventFollicular Lymphoma (FL)Indolent Non-FL B-NHL or MCLOther Disease
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/390/111/6
VIth nerve paralysisNervous system disorders0/390/111/6
NeutropeniaBlood and lymphatic system disorders0/391/110/6
ThrombocytopeniaBlood and lymphatic system disorders2/391/110/6
PneumoniaInfections and infestations1/391/110/6
HaemothoraxRespiratory, thoracic and mediastinal disorders0/391/110/6
InfluenzaInfections and infestations0/391/110/6
Anogenital wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/391/110/6
Renal impairmentRenal and urinary disorders0/391/110/6
Decreased appetiteMetabolism and nutrition disorders2/390/110/6
Most frequent other events
Showing 10 of 129
Most frequent other events
EventFollicular Lymphoma (FL)Indolent Non-FL B-NHL or MCLOther Disease
ThrombocytopeniaBlood and lymphatic system disorders37/3910/115/6
DiarrhoeaGastrointestinal disorders28/399/115/6
NeutropeniaBlood and lymphatic system disorders29/397/112/6
LeukopeniaBlood and lymphatic system disorders20/398/113/6
Decreased appetiteMetabolism and nutrition disorders27/396/113/6
LymphopeniaBlood and lymphatic system disorders13/397/110/6
NauseaGastrointestinal disorders24/397/113/6
FatigueGeneral disorders22/395/112/6
DysgeusiaNervous system disorders14/393/113/6
NasopharyngitisInfections and infestations19/394/111/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Follicular Lymphoma (FL)Indolent Non-FL B-NHL or MCLOther DiseaseTotal
Mean57.4 ± 10.462.9 ± 9.756.3 ± 10.558.4 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Follicular Lymphoma (FL)Indolent Non-FL B-NHL or MCLOther DiseaseTotal
Female244230
Male157426
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Follicular Lymphoma (FL)Indolent Non-FL B-NHL or MCLOther DiseaseTotal
Hispanic or Latino0000
Not Hispanic or Latino3911656
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Follicular Lymphoma (FL)Indolent Non-FL B-NHL or MCLOther DiseaseTotal
American Indian or Alaska Native0000
Asian3911656
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Ogura M, Ando K, Suzuki T, Ishizawa K, Oh SY, Itoh K, Yamamoto K, Au WY, Tien HF, Matsuno Y, Terauchi T, Yamamoto K, Mori M, Tanaka Y, Shimamoto T, Tobinai K, Kim WS. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2014 Jun;165(6):768-76. doi: 10.1111/bjh.12819. Epub 2014 Mar 12. PubMed 24617454 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2009 to primary completion in Sep 2011, 28 months.

Results were first posted in Oct 2020, 9 years 1 month after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Lymphoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 28 months is below that.

Counting every sponsor, half of 293 studies reached it within 61 months; a quarter within 36 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2009
First posted
Apr 3, 2009
StartActual
Apr 15, 2009
Primary completionActual
Sep 6, 2011
CompletionActual
Feb 8, 2019
Results first posted
Oct 29, 2020
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00875056
Responsible party
Sponsor
First posted
Apr 3, 2009
Start date
Apr 15, 2009
Primary completion
Sep 6, 2011
Completion
Feb 8, 2019
Results posted
Oct 29, 2020
Last update
Jan 30, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion